描述
Abiraterone Acetate Tablets Product Specifications
Attribute | Details |
---|---|
Product Name | Abiraterone Acetate Tablets (Hengrui) |
Dosage & Quantity | 250?mg per tablet; 120 tablets per bottle |
Formulation | Oral film-coated tablet |
Approval No. | China NMPA H20193205 |
Product Code | 86980435000069 |
Manufacturer | Chengdu Shengdi Pharmaceutical Co., Ltd. |
Intended Use | Research use only—Not for human or veterinary use |
Mechanism of Action
Abiraterone acetate is a CYP17A1 inhibitor, strategically blocking both 17??hydroxylase and 17,20?lyase activities—thus inhibiting androgen synthesis in testes, adrenals, and prostate tumors. Ultimately, it reduces testosterone levels supporting prostate cancer growth
Research & Clinical Highlights
-
Widely used in castrate-resistant prostate cancer (CRPC) internationally fr.wikipedia.org+6xian-janssen.com.cn+6pmc.ncbi.nlm.nih.gov+6.
-
Clinical trials (e.g., STAMPEDE) showed significant overall survival benefit when added to standard hormone therapy en.wikipedia.org+1icr.ac.uk+1.
-
Pharmacokinetics: high protein binding (~99.8%), half-life 12–24?h, predominantly excreted in feces (~88%)
Research Applications
Ideal for use in:
-
In vitro/in vivo prostate cancer models, especially CRPC
-
Drug combination and pathway modulation studies
-
Steroidogenesis and androgen-receptor signaling research
Handling & Storage
-
Storage: Room temperature (20–25?°C), keep bottle tightly sealed
-
Handling: Use standard lab PPE (gloves, goggles, lab coat)
-
Packaging: Bottle containing blister packs; verify seals before use
References
-
Mechanism & pharmacology summary icr.ac.uk+15pmc.ncbi.nlm.nih.gov+15sciencedirect.com+15
-
Clinical efficacy and survival benefit data
-
Pharmacokinetic parameters & protein binding
-
China regulatory info & product details (NMPA H20193205)
Yogurt –
Waited for 10 days, looking forward to it being useful